A comprehensive survival and prognosis analysis of GPR55 expression in hepatocellular carcinoma

Sep 24, 2026

Uploaded by Cart

Hepatocellular carcinoma (HCC) is the predominant primary liver cancer, shaped by a distinctive immune microenvironment that strongly influences disease onset, progression, and therapy response. With immune checkpoint inhibitors (ICIs) and VEGF-targeted strategies increasingly used for advanced HCC, identifying reliable biomarkers for predicting immunotherapy outcomes is urgent. This study reviews and analyzes GPR55, a lysophosphatidylinositol receptor, exploring its clinical significance and links to immune responses to support improved prognostic assessment.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages18

Reading Time45 min

AccessFree to download

Abstract

Introduction

Methods

Comprehensive bioinformatics analysis

[www.aging-us.com](www.aging-us.com) AGING 2023, Vol. 15, No. 17 Research Paper A comprehensive survival and prognosis analysis of GPR55 expression in hepatocellular carcinoma Tianyu Wang1,3,*, Kang Xia1,3,*, Tao Qiu1,2, Shangting Han1,2, Zhongbao Chen1,2, Xiaoxiong Ma1,2, Long Zhang 1,2, Jilin Zou 1,2, Yalong Zhang1,2, Bo Yu1,2, Chenyang Kong1,2, Jiayu Guo1,2, Yiting Liu1,2, Jiangqiao Zhou 1,2, Shusen Zheng 1,4,5,6,7 1 Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, China 2 Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China 3 Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan, China 4 Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China 5 NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China 6 Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China 7 Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou 310003, Zhejiang, China * Equal contribution and co-first authors Correspondence to: Jiangqiao Zhou, Shusen Zheng; email: [zhoujq@whu.edu.cn](zhoujq@whu.edu.cn), [shusenzheng@zju.edu.cn](shusenzheng@zju.edu.cn)[ ](shusenzheng@zju.edu.cn)[Keywords:](Keywords: survival and prognosis analysis)[ survival and prognosis analysis](Keywords: survival and prognosis analysis), GPR55, hepatocellular carcinoma, mitogen-activated protein kinase signaling pathway Received: May 1, 2023 Accepted: August 20, 2023 Published: September 8, 2023 Copyright: © 2023 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Hepatocellular carcinoma (HCC) is the most common subtype, accounting for about 90% of all primary liver cancers. The liver is rich in a large number of immune cells, thus forming a special immune microenvironment, which plays a key role in the occurrence and development of hepatocellular carcinoma. Nowadays, tumor immunotherapy has become one of the most promising cancer treatment methods. Immune checkpoint inhibitors (ICIs) combined with VEGF inhibitors are listed as first-line treatment options for advanced HCC. Therefore, the search for a potential biomarker to predict the response to immunotherapy in HCC patients is urgently needed. The G protein-coupled receptor 55 (GPR55), a lysophosphatidylinositol (LPI) receptor, has recently emerged as a potential new target for anti-tumor therapy. Previous studies have found that GPR55 is highly expressed in breast cancer, pancreatic cancer, skin cancer and cholangiocarcinoma, and is involved in tumor proliferation and migration. However, the role and mechanism of GPR55 in HCC has not been elucidated. Therefore, this article discusses the clinical significance of GPR55 in HCC and its correlation with the immune response of HCC patients, to provide theoretical basis for improving the prognosis of HCC. INTRODUCTION Liver cancer, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma, is the fifth most common malignant neoplasm in the United States [1] . Most HCC patients are diagnosed when already in an advanced stage due to the potential difficulties in their early detection [2] . As advanced HCC is highly malignant with rapid progression, treatment for these patients is difficult and the therapeutic effect is generally unsatisfactory, leading to undesirable survival outcomes. Due to the promising efficacy in patients with advanced tumor-stage melanoma or lung cancer, immunotherapy

FAQs

Why is finding a biomarker for advanced HCC immunotherapy response important?

Advanced HCC has limited effective treatments and tumor immune recognition is crucial. Biomarkers are needed to predict how patients will respond to immune checkpoint inhibitors and to refine prognosis.

What is GPR55, and why is it considered a potential target in cancer?

GPR55 is a G protein-coupled receptor (a lysophosphatidylinositol receptor) that has been linked to tumor proliferation and migration in prior studies and may influence immune responses.

What is the document’s main objective regarding GPR55 in HCC?

To investigate the clinical significance of GPR55 in hepatocellular carcinoma and clarify its correlation with the immune response to provide theoretical support for improving HCC prognosis.

Sep 24, 2026

Uploaded by Cart